116 related articles for article (PubMed ID: 25736768)
1. Assessment of canonical NF-κB activity in canine diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Mason NJ
Methods Mol Biol; 2015; 1280():469-504. PubMed ID: 25736768
[TBL] [Abstract][Full Text] [Related]
2. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
[TBL] [Abstract][Full Text] [Related]
3. A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.
Habineza Ndikuyeze G; Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Flood P; Krick E; Propert KJ; Mason NJ
PLoS One; 2014; 9(5):e95404. PubMed ID: 24798348
[TBL] [Abstract][Full Text] [Related]
4. Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).
Mudaliar MA; Haggart RD; Miele G; Sellar G; Tan KA; Goodlad JR; Milne E; Vail DM; Kurzman I; Crowther D; Argyle DJ
PLoS One; 2013; 8(9):e72591. PubMed ID: 24023754
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
[TBL] [Abstract][Full Text] [Related]
6. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
[TBL] [Abstract][Full Text] [Related]
7. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
[TBL] [Abstract][Full Text] [Related]
9. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Kloo B; Nagel D; Pfeifer M; Grau M; Düwel M; Vincendeau M; Dörken B; Lenz P; Lenz G; Krappmann D
Proc Natl Acad Sci U S A; 2011 Jan; 108(1):272-7. PubMed ID: 21173233
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.
Nagel D; Vincendeau M; Eitelhuber AC; Krappmann D
Oncogene; 2014 Dec; 33(50):5655-65. PubMed ID: 24469030
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.
Cerhan JR; Liu-Mares W; Fredericksen ZS; Novak AJ; Cunningham JM; Kay NE; Dogan A; Liebow M; Wang AH; Call TG; Habermann TM; Ansell SM; Slager SL
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3161-9. PubMed ID: 18990758
[TBL] [Abstract][Full Text] [Related]
12. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T; Mar JC; Du Y; Fu H; Mann KP; Natkunam Y; Boise LH; Saavedra HI; Lossos IS; Bernal-Mizrachi L
Int J Cancer; 2015 May; 136(10):2341-51. PubMed ID: 25359525
[TBL] [Abstract][Full Text] [Related]
13. Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma.
Turturro F
Biomed Res Int; 2015; 2015():484537. PubMed ID: 25984532
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.
Thomas RK; Sos ML; Zander T; Mani O; Popov A; Berenbrinker D; Smola-Hess S; Schultze JL; Wolf J
Clin Cancer Res; 2005 Nov; 11(22):8186-94. PubMed ID: 16299251
[TBL] [Abstract][Full Text] [Related]
15. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.
Guo F; Sun A; Wang W; He J; Hou J; Zhou P; Chen Z
Mol Immunol; 2009 Aug; 46(13):2441-8. PubMed ID: 19540595
[TBL] [Abstract][Full Text] [Related]
16. Relationship between constitutive nuclear factor-kappaB (NF-kappaB) and inhibitor kappaB-alpha (IkappaB-alpha) in an interferon-alpha-sensitive human Burkitt lymphoma cell line.
Rath PC
Biochim Biophys Acta; 2005 Sep; 1741(3):253-63. PubMed ID: 15979856
[TBL] [Abstract][Full Text] [Related]
17. NEMO-binding domain peptide inhibition of inflammatory signal-induced NF-κB activation in vivo.
McCorkell KA; May MJ
Methods Mol Biol; 2015; 1280():505-25. PubMed ID: 25736769
[TBL] [Abstract][Full Text] [Related]
18. β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma.
Cai N; Chen Z; Huang Y; Shao S; Yu H; Wang Y; He S
Cancer Biol Ther; 2020; 21(3):241-247. PubMed ID: 31731887
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.
Seelig DM; Ito D; Forster CL; Yoon UA; Breen M; Burns LJ; Bachanova V; Lindblad-Toh K; O'Brien TD; Schmechel SC; Rizzardi AE; Modiano JF; Linden MA
Leuk Lymphoma; 2017 Jul; 58(7):1702-1710. PubMed ID: 27931134
[TBL] [Abstract][Full Text] [Related]
20. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
